Comparing two types of PET scans for cancer diagnosis
Official title: Comparison of FDG and FAPI in Patients With Various Types of Cancer
Run by The First Affiliated Hospital of Xiamen University · NCT04416165 · Data updated 2026-11-12
This study is testing whether a new type of PET scan can find cancer better than the standard scan in patients who have or might have tumors.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 90 Years |
| Sex | All |
| Enrollment | 3000 (estimated) |
| Sponsor | The First Affiliated Hospital of Xiamen University Academic / other |
| Locations | 1 site (Xiamen, Fujian) |
| Status | Recruiting |
| Started | October 20, 2019 |
| Main results expected | December 30, 2027 |
| Study ends | December 30, 2027 |
| Registry record updated | August 8, 2023 |
| Trial ID | NCT04416165 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adult patients aged 18 or older with suspected or diagnosed malignant tumors who can provide informed consent.
✕Probably not a fit
Patients with non-malignant lesions or those who are pregnant will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the effectiveness of 68Ga-DOTA-FAPI-04 positron emission tomography/computed tomography (PET/CT) in diagnosing primary and metastatic lesions in various cancers, compared to the standard 18F-FDG PET/CT. Patients with suspected or diagnosed malignant tumors will undergo both types of scans, and the results will be analyzed for sensitivity, specificity, and overall diagnostic accuracy. The goal is to determine which imaging method provides better diagnostic information for cancer detection and monitoring.
Why it matters
Potential benefit: If successful, this study could improve the accuracy of cancer diagnosis and monitoring, leading to better patient outcomes.
How similar studies have gone: Other studies have shown promising results with similar imaging techniques, suggesting potential for success in this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * (i) adult patients (aged 18 years or order); (ii) patients with suspected or newly diagnosed or previously treated malignant tumors (supporting evidence may include magnetic resonance imaging (MRI), CT, tumor markers and pathology report); (iii) patients who had scheduled both 18F-FDG and 68Ga-DOTA-FAPI-04 PET/CT scans; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee. Exclusion Criteria: * (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.
Where it's running
-
First affiliated hospital of xiamen university
Xiamen, Fujian, China Recruiting
Study contacts
- Study coordinator: Hua Wu, PhD
- Email: wuhua1025@163.com
- Phone: 86 0592-2137166
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Evaluating PSMA PET/CT Imaging for Prostate Cancer Patients
This study is testing a special type of imaging called PSMA PET/CT to see if it can help find cancer in adults who have or might have prostate cancer.
-
Evaluating PET/CT for SSTR-related diseases
This study is testing a new type of PET/CT scan to see if it can help find cancer spots in adults who have tumors related to SSTR diseases.
-
Imaging CXCR4-related diseases using PET/CT
This study is testing a new type of imaging to see if it can better identify and track diseases related to CXCR4 in patients.
-
Evaluating FAPI PET/CT for Diagnosing FAP-Related Diseases
This study is testing if a special type of scan can help find cancer in adults who have or might have tumors related to FAP.
-
68Ga-FAPI PET/CT imaging to detect primary and metastatic cancer lesions
This study tests whether 68Ga-DOTA/NOTA-FAPI-04 PET/CT can help find primary tumors and metastases in adults with various cancers.
-
PD-L1 PET/CT to see primary and metastatic PD-L1-related lesions in adults
This study tests whether 68Ga/18F-PD-L1 PET/CT can help detect primary and metastatic PD-L1-related tumors in adults.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.